Repros Therapeutics (RPRX) Issues Update on Enclomiphene Study vs. Diet and Exercise in Secondary Hypogonadal Men
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall St drops as Meta Platforms, economic data weigh
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Dollar firmer on higher U.S. inflation; yen sinks vs euro, US currency
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Repros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
August 15, 2016 4:01 PM EDTSix month interim assessment of testosterone (T) levels shows statistically and clinically significant increases in total T (p = 0.0017) and free T (p = 0.0020) superior to placeboEffects of diet and exercise and enclomiphene treatment are additive Diet and exercise alone increased mean total T (263.9 ng/dL to 368.2 ng/dL, p = 0.0055) and mean free T (55.6 pg/mL to 57.1 pg/mL, p = 0.0802) Enclomiphene treatment combined with diet and exercise increased mean total T (277.3 ng/dL to 780.9 ng/dL, p... More
